<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258995</url>
  </required_header>
  <id_info>
    <org_study_id>C1091007</org_study_id>
    <nct_id>NCT04258995</nct_id>
  </id_info>
  <brief_title>A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS</brief_title>
  <official_title>A PHASE 2, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an extension to the completed first-in-human C1091001 study (NCT03170609) and&#xD;
      is to evaluate the safety and immunogenicity of a single booster vaccine dose of GBS6,&#xD;
      administered approximately 2 years or more after a primary GBS6 dose, to healthy adult males&#xD;
      and nonpregnant women. The study will determine whether individuals who received a primary&#xD;
      dose of GBS6 have additional benefit following a booster dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Actual">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are two arms in the study however based on the prior formulation received participants can only be enrolled into one predetermined arm in the study. Participants are assigned by an interactive response technology (IRT) based on prior formulation received.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Prompted Local Reactions Within 14 Days Following Booster Dose (Redness, Swelling, and Pain at the Injection Site)</measure>
    <time_frame>Within 14 days after booster dose</time_frame>
    <description>Local reactions were collected by using an e-diary and included pain at injection site, redness, and swelling graded below: pain at injection site: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever &gt;24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity), grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.0-5.0 centimeter [cm]), moderate (greater than [&gt;] 5.0-10.0 cm),severe (&gt;10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis).Maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Prompted Systemic Events Within 14 Days Following Booster Dose (Fever, Nausea/Vomiting, Diarrhea, Headache, Fatigue, Muscle Pain, and Joint Pain)</measure>
    <time_frame>Within 14 days after booster dose</time_frame>
    <description>Nausea/Vomiting:Mild:No interference with activity or 1-2 times in 24 hours;Moderate:Some interference with activity or&gt;2 times in 24 hours;Severe:Prevented daily activity, required IV hydration.Diarrhea:Mild:2-3 loose stools in 24 hours;Moderate: 4-5 loose stools in 24 hours;Severe:&gt;=6 loose stools in 24 hours.Headache:Mild:No interference with activity;Moderate:Repeated use of nonnarcotic pain reliever &gt;24 hours or some interference with activity;Severe:Significant; any use of narcotic pain reliever or prevents daily activity.Fatigue:Mild:No interference with activity;Moderate: Some interference with activity;Severe: Significant; prevented daily activity.Muscle pain:Mild: No interference with activity;Moderate:Some interference with activity;Severe:Significant;prevented daily activity.Muscle/joint pain:Mild: No interference with activity;Moderate:Some interference with activity;Severe:Significant; prevented daily activity.Grade 4 for all AEs:Emergency visit or hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month Following Booster Dose</measure>
    <time_frame>Within 1 month after booster dose</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) Within 6 Months Following Booster Dose</measure>
    <time_frame>Within 6 months after booster dose</time_frame>
    <description>An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Booster Dose</measure>
    <time_frame>Within 6 months after booster dose</time_frame>
    <description>An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GBS Serotype-Specific IgG Geometric Mean Concentrations (GMC) Measured Before and 1 Month After Booster Dose</measure>
    <time_frame>Before and 1 month after booster dose</time_frame>
    <description>Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GBS Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers Measured Before to 1 Month After Booster Dose</measure>
    <time_frame>Within 6 months after primary dose and within 1 month after booster dose</time_frame>
    <description>OPA for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GBS Serotype-Specific IgG Geometric Mean Fold Rise (GMFR) From Before To 1 Month After Booster Dose</measure>
    <time_frame>1 month after booster dose</time_frame>
    <description>IgG for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GBS Serotype-Specific OPA GMFR Measured Before and 1 Month After Booster Dose</measure>
    <time_frame>1 month after booster dose</time_frame>
    <description>OPA for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GBS Serotype-Specific IgG GMC Measured 1 Month After Booster Dose Stratified by Baseline Pre-vaccination Status (Before the Primary Dose)</measure>
    <time_frame>1 month after booster dose</time_frame>
    <description>Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V. The pre-vaccination immunogenicity blood draw and booster vaccination were both performed on Day 1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Group B Streptococcal Infections</condition>
  <arm_group>
    <arm_group_label>GBS6 no aluminum phosphate (GBS6 no AlPO4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GBS6 with aluminum phosphate (GBS6 with AlPO4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)</intervention_name>
    <description>2 formulations at 1 dose level</description>
    <arm_group_label>GBS6 no aluminum phosphate (GBS6 no AlPO4)</arm_group_label>
    <arm_group_label>GBS6 with aluminum phosphate (GBS6 with AlPO4)</arm_group_label>
    <other_name>GBS6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults (male and female) at enrollment who are determined by medical history,&#xD;
             physical examination, and clinical judgment of the investigator to be eligible for&#xD;
             inclusion in the study.&#xD;
&#xD;
          2. Participants who were enrolled in the C1091001 study, received GBS6, and completed the&#xD;
             1-month blood draw.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant female participants; breastfeeding female participants; positive urine&#xD;
             pregnancy test for women of childbearing potential (WOCBP) at Visit 1 (prior to&#xD;
             vaccination); and WOCBP who are, in the opinion of the investigator, sexually active&#xD;
             and at risk for pregnancy and fertile men and WOCBP who are unwilling or unable to use&#xD;
             effective methods of contraception as outlined in this protocol from the signing of&#xD;
             the informed consent until at least 3 months after the last dose of investigational&#xD;
             product.&#xD;
&#xD;
          2. Acute or chronic medical or psychiatric condition or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the participant inappropriate for entry into&#xD;
             this study. Chronic medical conditions include human immunodeficiency virus, chronic&#xD;
             hepatitis B virus (HBV) infection (HBV surface antigen positive), and/or hepatitis C&#xD;
             virus infection.&#xD;
&#xD;
          3. History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis)&#xD;
             to any vaccine.&#xD;
&#xD;
          4. History of microbiologically proven invasive disease caused by group B streptococcus&#xD;
             (Streptococcus agalactiae).&#xD;
&#xD;
          5. Previous vaccination with any licensed or investigational group B streptococcus&#xD;
             vaccine (other than GBS6), or planned receipt during the participant's participation&#xD;
             in the study (through 6-month telephone call).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric &amp; Adult Research Inc.</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc./ Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C1091007</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <results_first_submitted>August 18, 2021</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT04258995/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT04258995/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Overall, a total of 151 participants were assigned and vaccinated with a single booster dose of group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) (20 microgram [μg] capsular polysaccharide [CPS]/serotype/dose) formulated with or without aluminum phosphate (AlPO4) based on the formulation received in the primary C1091001 study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GBS6 20 μg With AlPO4</title>
          <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
        </group>
        <group group_id="P2">
          <title>GBS6 20 μg Without AlPO4</title>
          <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received 1 booster dose and had at least 1 safety assessment after receiving the booster dose.</population>
      <group_list>
        <group group_id="B1">
          <title>GBS6 20 μg With AlPO4</title>
          <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
        </group>
        <group group_id="B2">
          <title>GBS6 20 μg Without AlPO4</title>
          <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="8.40"/>
                    <measurement group_id="B2" value="36.2" spread="8.96"/>
                    <measurement group_id="B3" value="36.7" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Prompted Local Reactions Within 14 Days Following Booster Dose (Redness, Swelling, and Pain at the Injection Site)</title>
        <description>Local reactions were collected by using an e-diary and included pain at injection site, redness, and swelling graded below: pain at injection site: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever &gt;24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity), grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.0-5.0 centimeter [cm]), moderate (greater than [&gt;] 5.0-10.0 cm),severe (&gt;10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis).Maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.</description>
        <time_frame>Within 14 days after booster dose</time_frame>
        <population>All the participants reporting &quot;yes&quot; or &quot;no&quot; for at least 1 day were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Prompted Local Reactions Within 14 Days Following Booster Dose (Redness, Swelling, and Pain at the Injection Site)</title>
          <description>Local reactions were collected by using an e-diary and included pain at injection site, redness, and swelling graded below: pain at injection site: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever &gt;24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity), grade 4 (emergency room visit or hospitalization). Redness and swelling were graded as: mild (2.0-5.0 centimeter [cm]), moderate (greater than [&gt;] 5.0-10.0 cm),severe (&gt;10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis).Maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.</description>
          <population>All the participants reporting &quot;yes&quot; or &quot;no&quot; for at least 1 day were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="56.7" upper_limit="78.6"/>
                    <measurement group_id="O2" value="42.7" lower_limit="31.3" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" lower_limit="42.1" upper_limit="65.5"/>
                    <measurement group_id="O2" value="38.7" lower_limit="27.6" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="5.6" upper_limit="21.3"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.8" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.3" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.3" upper_limit="9.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.8" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.3" upper_limit="9.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.8" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Prompted Systemic Events Within 14 Days Following Booster Dose (Fever, Nausea/Vomiting, Diarrhea, Headache, Fatigue, Muscle Pain, and Joint Pain)</title>
        <description>Nausea/Vomiting:Mild:No interference with activity or 1-2 times in 24 hours;Moderate:Some interference with activity or&gt;2 times in 24 hours;Severe:Prevented daily activity, required IV hydration.Diarrhea:Mild:2-3 loose stools in 24 hours;Moderate: 4-5 loose stools in 24 hours;Severe:&gt;=6 loose stools in 24 hours.Headache:Mild:No interference with activity;Moderate:Repeated use of nonnarcotic pain reliever &gt;24 hours or some interference with activity;Severe:Significant; any use of narcotic pain reliever or prevents daily activity.Fatigue:Mild:No interference with activity;Moderate: Some interference with activity;Severe: Significant; prevented daily activity.Muscle pain:Mild: No interference with activity;Moderate:Some interference with activity;Severe:Significant;prevented daily activity.Muscle/joint pain:Mild: No interference with activity;Moderate:Some interference with activity;Severe:Significant; prevented daily activity.Grade 4 for all AEs:Emergency visit or hospitalization.</description>
        <time_frame>Within 14 days after booster dose</time_frame>
        <population>All the participants reporting &quot;yes&quot; or &quot;no&quot; for at least 1 day were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Prompted Systemic Events Within 14 Days Following Booster Dose (Fever, Nausea/Vomiting, Diarrhea, Headache, Fatigue, Muscle Pain, and Joint Pain)</title>
          <description>Nausea/Vomiting:Mild:No interference with activity or 1-2 times in 24 hours;Moderate:Some interference with activity or&gt;2 times in 24 hours;Severe:Prevented daily activity, required IV hydration.Diarrhea:Mild:2-3 loose stools in 24 hours;Moderate: 4-5 loose stools in 24 hours;Severe:&gt;=6 loose stools in 24 hours.Headache:Mild:No interference with activity;Moderate:Repeated use of nonnarcotic pain reliever &gt;24 hours or some interference with activity;Severe:Significant; any use of narcotic pain reliever or prevents daily activity.Fatigue:Mild:No interference with activity;Moderate: Some interference with activity;Severe: Significant; prevented daily activity.Muscle pain:Mild: No interference with activity;Moderate:Some interference with activity;Severe:Significant;prevented daily activity.Muscle/joint pain:Mild: No interference with activity;Moderate:Some interference with activity;Severe:Significant; prevented daily activity.Grade 4 for all AEs:Emergency visit or hospitalization.</description>
          <population>All the participants reporting &quot;yes&quot; or &quot;no&quot; for at least 1 day were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever:&gt;=38.0 degree C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 38.0°C to 38.4°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;38.4°C to 38.9°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.3" upper_limit="9.2"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;38.9°C to 40.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="3.0" upper_limit="16.4"/>
                    <measurement group_id="O2" value="10.7" lower_limit="4.7" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="2.2" upper_limit="14.7"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.5" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.5" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="8.4" upper_limit="26.0"/>
                    <measurement group_id="O2" value="16.0" lower_limit="8.6" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="7.5" upper_limit="24.4"/>
                    <measurement group_id="O2" value="10.7" lower_limit="4.7" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.5" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" lower_limit="20.2" upper_limit="41.9"/>
                    <measurement group_id="O2" value="41.3" lower_limit="30.1" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="12.5" upper_limit="31.9"/>
                    <measurement group_id="O2" value="26.7" lower_limit="17.1" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="3.8" upper_limit="18.1"/>
                    <measurement group_id="O2" value="13.3" lower_limit="6.6" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/tiredness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="33.3" upper_limit="56.6"/>
                    <measurement group_id="O2" value="30.7" lower_limit="20.5" upper_limit="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/tiredness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="14.7" upper_limit="34.8"/>
                    <measurement group_id="O2" value="20.0" lower_limit="11.6" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/tiredness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="11.5" upper_limit="30.5"/>
                    <measurement group_id="O2" value="9.3" lower_limit="3.8" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/tiredness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/tiredness: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="14.7" upper_limit="34.8"/>
                    <measurement group_id="O2" value="17.3" lower_limit="9.6" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="5.6" upper_limit="21.3"/>
                    <measurement group_id="O2" value="14.7" lower_limit="7.6" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="3.8" upper_limit="18.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.3" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="5.6" upper_limit="21.3"/>
                    <measurement group_id="O2" value="9.3" lower_limit="3.8" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="2.2" upper_limit="14.7"/>
                    <measurement group_id="O2" value="6.7" lower_limit="2.2" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month Following Booster Dose</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.</description>
        <time_frame>Within 1 month after booster dose</time_frame>
        <population>Safety population included all participants who received 1 booster dose and had at least 1 safety assessment after receiving the booster dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month Following Booster Dose</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.</description>
          <population>Safety population included all participants who received 1 booster dose and had at least 1 safety assessment after receiving the booster dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="2.2" upper_limit="14.7"/>
                    <measurement group_id="O2" value="12.0" lower_limit="5.6" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) Within 6 Months Following Booster Dose</title>
        <description>An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
        <time_frame>Within 6 months after booster dose</time_frame>
        <population>Safety population included all participants who received 1 booster dose and had at least 1 safety assessment after receiving the booster dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) Within 6 Months Following Booster Dose</title>
          <description>An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
          <population>Safety population included all participants who received 1 booster dose and had at least 1 safety assessment after receiving the booster dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="5.6" upper_limit="21.3"/>
                    <measurement group_id="O2" value="9.3" lower_limit="3.8" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Booster Dose</title>
        <description>An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.</description>
        <time_frame>Within 6 months after booster dose</time_frame>
        <population>Safety population included all participants who received the booster dose.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Booster Dose</title>
          <description>An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.</description>
          <population>Safety population included all participants who received the booster dose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GBS Serotype-Specific IgG Geometric Mean Concentrations (GMC) Measured Before and 1 Month After Booster Dose</title>
        <description>Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.</description>
        <time_frame>Before and 1 month after booster dose</time_frame>
        <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>GBS Serotype-Specific IgG Geometric Mean Concentrations (GMC) Measured Before and 1 Month After Booster Dose</title>
          <description>Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.</description>
          <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ia: Day 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.070" lower_limit="1.539" upper_limit="6.125"/>
                    <measurement group_id="O2" value="3.252" lower_limit="1.558" upper_limit="6.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ia: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.600" lower_limit="34.705" upper_limit="65.285"/>
                    <measurement group_id="O2" value="52.038" lower_limit="35.654" upper_limit="75.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Day 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.537" lower_limit="0.272" upper_limit="1.060"/>
                    <measurement group_id="O2" value="0.588" lower_limit="0.302" upper_limit="1.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.298" lower_limit="17.396" upper_limit="33.940"/>
                    <measurement group_id="O2" value="20.095" lower_limit="14.033" upper_limit="28.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Day 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.244" lower_limit="3.186" upper_limit="8.630"/>
                    <measurement group_id="O2" value="6.379" lower_limit="4.007" upper_limit="10.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.670" lower_limit="39.310" upper_limit="67.916"/>
                    <measurement group_id="O2" value="64.617" lower_limit="47.313" upper_limit="88.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Day 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.850" lower_limit="0.508" upper_limit="1.423"/>
                    <measurement group_id="O2" value="1.227" lower_limit="0.750" upper_limit="2.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.511" lower_limit="10.224" upper_limit="17.854"/>
                    <measurement group_id="O2" value="17.305" lower_limit="12.994" upper_limit="23.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Day 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.768" lower_limit="0.496" upper_limit="1.189"/>
                    <measurement group_id="O2" value="0.873" lower_limit="0.573" upper_limit="1.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.048" lower_limit="23.259" upper_limit="38.818"/>
                    <measurement group_id="O2" value="33.216" lower_limit="24.452" upper_limit="45.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Day 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.104" lower_limit="0.608" upper_limit="2.004"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.556" upper_limit="1.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.368" lower_limit="27.387" upper_limit="56.589"/>
                    <measurement group_id="O2" value="52.326" lower_limit="36.887" upper_limit="74.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GBS Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers Measured Before to 1 Month After Booster Dose</title>
        <description>OPA for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
        <time_frame>Within 6 months after primary dose and within 1 month after booster dose</time_frame>
        <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>GBS Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers Measured Before to 1 Month After Booster Dose</title>
          <description>OPA for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
          <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ia: Day 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1368" lower_limit="826" upper_limit="2266"/>
                    <measurement group_id="O2" value="1361" lower_limit="831" upper_limit="2228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ia: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9374" lower_limit="7164" upper_limit="12266"/>
                    <measurement group_id="O2" value="8809" lower_limit="6665" upper_limit="11643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Day 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3307" lower_limit="1993" upper_limit="5487"/>
                    <measurement group_id="O2" value="2734" lower_limit="1603" upper_limit="4662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28809" lower_limit="21345" upper_limit="38883"/>
                    <measurement group_id="O2" value="18550" lower_limit="12943" upper_limit="26586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Day 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3209" lower_limit="2266" upper_limit="4545"/>
                    <measurement group_id="O2" value="3659" lower_limit="2705" upper_limit="4950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16057" lower_limit="12486" upper_limit="20650"/>
                    <measurement group_id="O2" value="15317" lower_limit="11689" upper_limit="20071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Day 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="756" lower_limit="508" upper_limit="1126"/>
                    <measurement group_id="O2" value="641" lower_limit="432" upper_limit="951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3695" lower_limit="2776" upper_limit="4917"/>
                    <measurement group_id="O2" value="3339" lower_limit="2381" upper_limit="4681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Day 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5591" lower_limit="4295" upper_limit="7279"/>
                    <measurement group_id="O2" value="4617" lower_limit="3429" upper_limit="6217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22994" lower_limit="18192" upper_limit="29063"/>
                    <measurement group_id="O2" value="19710" lower_limit="15517" upper_limit="25035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Day 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2249" lower_limit="1498" upper_limit="3376"/>
                    <measurement group_id="O2" value="2324" lower_limit="1517" upper_limit="3560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10484" lower_limit="7993" upper_limit="13750"/>
                    <measurement group_id="O2" value="8802" lower_limit="6417" upper_limit="12073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GBS Serotype-Specific IgG Geometric Mean Fold Rise (GMFR) From Before To 1 Month After Booster Dose</title>
        <description>IgG for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
        <time_frame>1 month after booster dose</time_frame>
        <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>GBS Serotype-Specific IgG Geometric Mean Fold Rise (GMFR) From Before To 1 Month After Booster Dose</title>
          <description>IgG for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
          <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ia: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.504" lower_limit="9.452" upper_limit="25.430"/>
                    <measurement group_id="O2" value="16.003" lower_limit="9.800" upper_limit="26.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.282" lower_limit="27.919" upper_limit="73.441"/>
                    <measurement group_id="O2" value="34.191" lower_limit="21.272" upper_limit="54.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.853" lower_limit="6.783" upper_limit="14.313"/>
                    <measurement group_id="O2" value="10.130" lower_limit="6.822" upper_limit="15.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.889" lower_limit="10.138" upper_limit="24.902"/>
                    <measurement group_id="O2" value="14.100" lower_limit="9.453" upper_limit="21.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.133" lower_limit="26.569" upper_limit="57.638"/>
                    <measurement group_id="O2" value="38.063" lower_limit="26.189" upper_limit="55.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Month 1 - Booster Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.668" lower_limit="23.796" upper_limit="53.463"/>
                    <measurement group_id="O2" value="52.750" lower_limit="34.308" upper_limit="81.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GBS Serotype-Specific OPA GMFR Measured Before and 1 Month After Booster Dose</title>
        <description>OPA for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
        <time_frame>1 month after booster dose</time_frame>
        <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>GBS Serotype-Specific OPA GMFR Measured Before and 1 Month After Booster Dose</title>
          <description>OPA for the 6 serotypes (Ia, Ib, II, III, IV, V) were determined in all participants for each blood sample at Day 1 and at 1 month after booster dose.</description>
          <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ia: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.80" upper_limit="10.00"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.43" upper_limit="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="6.21" upper_limit="13.47"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.46" upper_limit="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.65" upper_limit="6.36"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.08" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.54" upper_limit="6.58"/>
                    <measurement group_id="O2" value="5.2" lower_limit="3.79" upper_limit="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.18" upper_limit="5.32"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.17" upper_limit="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Month 1 - Booster Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.27" upper_limit="6.65"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.63" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GBS Serotype-Specific IgG GMC Measured 1 Month After Booster Dose Stratified by Baseline Pre-vaccination Status (Before the Primary Dose)</title>
        <description>Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V. The pre-vaccination immunogenicity blood draw and booster vaccination were both performed on Day 1.</description>
        <time_frame>1 month after booster dose</time_frame>
        <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS6 20 μg With AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>GBS6 20 μg Without AlPO4</title>
            <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>GBS Serotype-Specific IgG GMC Measured 1 Month After Booster Dose Stratified by Baseline Pre-vaccination Status (Before the Primary Dose)</title>
          <description>Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V. The pre-vaccination immunogenicity blood draw and booster vaccination were both performed on Day 1.</description>
          <population>Evaluable immunogenicity population included participants who had received 1 booster dose (as assigned); had a Visit 2 blood draw within 27 to 45 days after booster dose administration; had at least 1 valid and determinate assay result at Visit 2; and had no major protocol violation.</population>
          <units>microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ia: Month 1 - Booster Dose Month 1 - Booster Dose = Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.766" lower_limit="0.000" upper_limit="30690052.300"/>
                    <measurement group_id="O2" value="148.088" lower_limit="50.544" upper_limit="433.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ia: Month 1 - Booster Dose Month 1 - Booster Dose = Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.396" lower_limit="34.343" upper_limit="65.412"/>
                    <measurement group_id="O2" value="45.843" lower_limit="30.695" upper_limit="68.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Month 1 - Booster Dose Month 1 - Booster Dose = Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.327" lower_limit="3.968" upper_limit="409.881"/>
                    <measurement group_id="O2" value="112.434" lower_limit="0.000" upper_limit="245914635.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ib: Month 1 - Booster Dose Month 1 - Booster Dose = Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.624" lower_limit="16.732" upper_limit="33.353"/>
                    <measurement group_id="O2" value="19.156" lower_limit="13.365" upper_limit="27.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Month 1 - Booster Dose Month 1 - Booster Dose = Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.611" lower_limit="105.577" upper_limit="340.534"/>
                    <measurement group_id="O2" value="52.439" lower_limit="18.337" upper_limit="149.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II: Month 1 - Booster Dose Month 1 - Booster Dose = Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.285" lower_limit="34.250" upper_limit="59.876"/>
                    <measurement group_id="O2" value="66.513" lower_limit="47.596" upper_limit="92.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Month 1 - Booster Dose Month 1 - Booster Dose = Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.612" lower_limit="4.268" upper_limit="119.786"/>
                    <measurement group_id="O2" value="18.368" lower_limit="6.559" upper_limit="51.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III: Month 1 - Booster Dose Month 1 - Booster Dose = Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.228" lower_limit="9.915" upper_limit="17.647"/>
                    <measurement group_id="O2" value="17.214" lower_limit="12.681" upper_limit="23.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Month 1 - Booster Dose Month 1 - Booster Dose = Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.545" lower_limit="0.000" upper_limit="347896565796"/>
                    <measurement group_id="O2" value="77.627" lower_limit="22.933" upper_limit="262.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV: Month 1 - Booster Dose Month 1 - Booster Dose = Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.661" lower_limit="23.021" upper_limit="38.216"/>
                    <measurement group_id="O2" value="32.046" lower_limit="23.360" upper_limit="43.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Month 1 - Booster Dose Month 1 - Booster Dose = Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.017" lower_limit="19.528" upper_limit="472.109"/>
                    <measurement group_id="O2" value="103.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V: Month 1 - Booster Dose Month 1 - Booster Dose = Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.465" lower_limit="25.698" upper_limit="54.622"/>
                    <measurement group_id="O2" value="51.842" lower_limit="36.385" upper_limit="73.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The time period for actively eliciting and collecting AEs and SAEs for each participant began from the time the participant provided informed consent, through and including Visit 2 (1 month after booster dose) for AEs and through and including Visit 3 for MAEs and SAEs (6 months after booster dose).</time_frame>
      <desc>Safety population are participants who received 1 dose of the investigational product and had at least 1 safety assessment after receiving the booster dose. Medical Dictionary for Regulatory Activities (MedDRA) v23.1 was followed for AE reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>GBS6 20 μg With AlPO4</title>
          <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) with AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated with AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
        </group>
        <group group_id="E2">
          <title>GBS6 20 μg Without AlPO4</title>
          <description>Participants who received a primary dose of GBS6 (5 μg, 10 µg, or 20 µg) without AlPO4 in Study C1091001 received a single booster dose of GBS6 (20 µg) formulated without AlPO4 intramuscularly on Day 1 and were followed up to 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

